The effect of human leukemia inhibitory factor (hLIF) on the development of atherosclerosis was investigated in an experimental animal model. Two conditions were examined: one in which lesions could arise because of the influence of both "injury" (cuffed vessel) and diet and one in which only the effect of diet could be significant in other areas of the vasculature (aorta).
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Corey S. Moran, Julie H. Campbell, Danielle L. Simmons, Gordon R. Campbell Abstract The effect of human leukemia inhibitory factor (hLIF) on the development of atherosclerosis was investigated in an experimental animal model. Two conditions were examined: one in which lesions could arise because of the influence of both "injury" (cuffed vessel) and diet and one in which only the effect of diet could be significant in other areas of the vasculature (aorta). At time zero, the right carotid artery of rabbits (n=32) was ensheathed in a soft Silastic cuff, and an osmotic minipump (2-mL capacity; 2.5 /xL/h; 28 days) containing either hLIF or saline was inserted into the peritoneal cavity. Rabbits were divided into four groups (n=8): group 1 received normal diet/saline; group 2, normal diet/LIF (30 /i.g • kg" 1 • d" 1 ); group 3, 1% cholesterol diet/saline; and group 4, 1% cholesterol diet/LIF (30 /u.g • kg" 1 • d~')-After 28 days, the cholesterol diet (group 3) resulted in a sixfold increase in plasma cholesterol level compared with group 1 rabbits on a normal diet (3.80±0.50 versus 0.55+0.01 mmol/L). This was significantly lower (f > =.01) with hLIF treatment in group 4 rabbits (2.80±0.44 mmol/L). Group 2 rabbits had higher aortic tissue cholesterol levels (1.40±0.35 mg/g) compared with group 1 rabbits on a normal diet (0.10±0.06 mg/g) (P=.01), whereas hLIF treatment decreased tissue cholesterol levels by 60% in group 4 rabbits (0.60±0.05 mg/g) (P=.01). Group 3 rabbits developed lipid-filled lesions covering 63.25±17.66% T he polyfunctional cytokine leukemia inhibitory factor (LIF) is a secreted glycoprotein. It was originally purified, characterized, and cloned by virtue of its ability to induce the terminal differentiation and suppression of clonogenicity of mouse Ml myeloid leukemic cells 1 -2 ; however, it is now clear that LIF possesses a diverse range of biological activities in a variety of tissue systems. 3 LIF acts directly or synergistically to stimulate proliferation of certain hemopoietic cells, 4 the release of acute-phase proteins by hepatocytes, 5 osteoblast/osteoclast activity, 6 -7 and myoblast proliferation (see Reference 3) . Human LIF inhibits adipocytic lipoprotein lipase activity, 8 directs neuron neurotransmitter choice and survival, 9 and induces cytokine expression in human blood monocytes. 10 -11 One of the earliest cellular events in the development of experimental atherosclerosis is the adhesion of circulating monocytes to the endothelium of targeted arteries. The attached monocytes migrate through the intact endothelium and then differentiate into macrophages, of the thoracic aorta surface, whereas lesions were significantly reduced (9.88+8.79%) (P=.01) with LIF treatment (group 4). No thoracic aorta lesions were present in groups 1 and 2. Cuff placement around the right carotid artery in groups 1 and 3 resulted in neointimal formation (as percent total wall crosssectional area) of 15.06+8.83% and 19.30±5.36%, respectively. In LIF-treated animals (groups 2 and 4), neointima composed only 2.12±5.45% and 2.09±4.32%, respectively, which represented a significant reduction (P=.01). Immunocytochemical analysis revealed no subendothelial macrophages in rabbits fed a normolipidic diet with or without hLIF treatment, but 153.60±15.60 and 165.30+22.40 (P=.677) macrophages per ring segment were found in animals fed a cholesterol diet in the presence and absence of hLIF, respectively. Together these results show that hLIF lowers plasma cholesterol and inhibits the development of aortic fatty streaks in cholesterol-fed rabbits. hLIF also inhibits the development of cuff-induced carotid neointimal thickening in rabbits fed either a normal or cholesterol diet but does not affect monocyte invasion of the vessel wall. 1213 Besides the contribution of these cells to the formation of fatty streaks through engorgement of lipid, a myriad of smooth muscle cell (SMC) growth factors can be produced by the macrophage that can potentially contribute to the proliferative processes of atheroma development.
14 -15 LIF, along with other factors such as interleukin-6, granulocyte-colony stimulating factor, and macrophage-colony stimulating factor, is rapidly released into the serum of mice treated with an inflammatory mediator lipopolysaccharide, 16 suggesting a role for LIF in modulating an acute inflammatory response. It was reasoned, therefore, that LIF may influence the developing stages of atherosclerosis through modulating monocyte/macrophage invasion of the vessel wall.
To test this hypothesis, we investigated the effect of recombinant human LIF (hLIF) (administered via an intraperitoneal osmotic pump) on neointimal formation and fatty streak development in a rabbit model under both normolipidemic and hyperlipidemic conditions. A perivascular Silastic cuff was used to induce an inflammation-mediated neointimal thickening in the right carotid artery of the rabbits in the presence of an intact endothelium. 1719 Established hematologic and biological parameters affected by LIF 20 were used to test the biological action of hLIF in the rabbit, thus validating the investigation. We report here that hLIF significantly lowers plasma cholesterol levels, with concomitant de-creased lipid deposition and fatty streak formation in the thoracic aorta, and effectively inhibits development of an SMC-rich neointimal thickening in the cuffed carotid artery without influencing monocyte/macrophage invasion.
Methods hLIF
hLIF was supplied by the Australian Medical Research and Development (AMRAD) Corp. The recombinant hLIF was produced by use of the pGEX bacterial (Escherichia coli) expression system 21 and purified to homogeneity as described by Gearing et al.
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Animals
Male 18-week-old New Zealand White rabbits weighing approximately 2.30 kg were obtained from commercial colonies. They were individually caged under a 12-hour day/night cycle and fed ad libitum with water, fruit and vegetables, and standard rabbit chow.
Cholesterol Diet
Hyperlipidemia was induced in 16 of the rabbits via a 1% (wt/wt) cholesterol-supplemented diet. Normal rabbit pellets were combined thoroughly with a 2% cholesterol solution that was evaporated for 24 hours in a fume hood before being mixed with chaff in a 50:50 ratio, resulting in an overall 1% cholesterol diet. The hyperlipidemic diet was commenced immediately after animal surgery.
Surgery
AH major surgical procedures were carried out under general anesthesia. Each animal was preanesthetized with 1 mL alphaxalone 90 mg/alphadolone acetate 30 mg IV (Saffan, Glaxovet) injected into the marginal ear vein. The animals were intubated with a pediatric endotracheal tube (Portex) that allowed continual anesthesia with a variable mixture of halothane (Fluothane, ICI) and air from a Golman vaporizer.
The right carotid artery was exposed by midline incision and isolated from surrounding connective tissue. A nonocclusive, biologically inert, soft and flexible Silastic cuff of polyethylene tubing was placed around the artery, ensheathing a length of approximately 2.0 cm. The artery was repositioned and the skin wound sutured (subcircular stitch, 3/0 Dermalon, Cyanamid). At the same time, an abdominal midline incision allowed intraperitoneal placement of an Alzet osmotic minipump (model 24ML, ALZA Corp) containing either hLIF or vehicle (phosphate-buffered saline, PBS). These pumps deliver 2.5 j/.L/h, with a mean volume of 2.167 mL, and therefore are potentially active for 36 days. After incision and pump insertion, the muscular layer and skin wound were sutured (singular stitch, 3/0 Dermalon, Cyanamid). At the completion of the operation, each animal was given single injections of heparin (1000 U IV, DBL) and the antibiotic amoxycillin (500 U IM, CSL).
Osmotic Pump Preparation
On the day of and just before surgery, all pumps were prerinsed with 2% clinical-grade bovine serum albumin (BSA) (ICN Biochemicals) before being filled with either hLIF or freshly prepared PBS (2% KCI, 2% NaH 2 PO 4 , 84% NaCl, and 12% anhydrous Na 2 HPO 4 ) (all chemicals from Sigma Chemical Co). For LIF treatment, a constant animal weight of 2.5 kg over the 28-day treatment period was assumed, and since the required dose used was 30 fig • kg" 1 • d" ! , 2.1 mL of 1.0 mg/mL LIF was injected into the osmotic pumps at an administration rate of 2.5 /xL/h. This, theoretically, should leave 420 £iL spare in the pump. Actual volumes collected from the individual pumps at termination ranged from 0 to 500 /xL.
The same volume of PBS was injected into the control pumps. All filled pumps were kept in sterile 0.9% NaCl solution until use for peritoneal insertion.
Silastic Cuff Preparation
Perivascular cuffs were made from two pieces of polyethylene Silastic tubing (Precision Surgical Supplies). The outer and inner diameters of the large and small tubing were 3.18 and 1.98 mm and 1.96 and 1.42 mm, respectively. The largerdiameter tubing was cut into 20-mm lengths and the smaller into 2-mm lengths. The 20-mm sections were cut longitudinally along one "side" to allow luminal attachment of the 2-mm segments with silicone glue (Dow Corning) at each end of the 20-mm section. The inner 2-mm rings at either end of the cuff served to hold the structure in place without significant occlusion of the test vessel by the tubing.
After 24 hours of hardening of the glue, the cuff was recut longitudinally at its ends to allow perivascular placement. Cuffs underwent autoclave sterilization before surgical use.
Hematology
Before surgery, then on a weekly basis and at termination, all animals were bled (2.5 mL) via the central ear artery for hematologic analysis. Blood was collected in EDTA-coated sample tubes using Jelco catheter placement units (22G, Critikon) with the aid of a local anesthetic, Xylocaine (lignocaine 1%, DBL). All samples were analyzed for platelet number, erythrocyte sedimentation rate (ESR), and serum calcium and albumin levels.
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Animal Termination
All animals were killed 28 days after placement of the carotid cuffs and osmotic pumps. Anesthesia was induced and maintained with Saffan via catheter placement in the marginal ear vein. Blood was collected via cardiac puncture into tubes rinsed with 0.08 mol/L EDTA and centrifuged, and plasma was stored at -20°C until analyzed for cholesterol content and lipoprotein fractionation.
Each animal was then killed with an overdose of 350 mg/mL sodium pentobarbitone (Euthatal) (Rhone Merieux). The spleen and thymus were excised and fixed in 10% neutral buffered formal saline (BFS) (Conform, Medos Corp), sectioned at 6 /um, and prepared for hematoxylin and eosin staining and examination by light microscopy. Each osmotic minipump was recovered, and the volume of remaining content, if any, was recorded.
Aorta
The aortic arch and thoracic aorta were dissected free, and the thoracic aorta was fixed and stored in 10% BFS, cut longitudinally, and flattened to permit en face luminal staining. The luminal surface was stained (60 seconds) with 0.5% wt/vol oil red O (Sigma Chemical Co) in 60% isopropyl alcohol; this rendered lipid-containing regions red. The percent area of the luminal surface covered by fatty streak was then determined morphometrically by point-counting techniques.
The aortic arch was sampled at the same points of the vessel for each animal, weighed, and stored at -70°C for total tissue cholesterol determination by a cold chloroform-methanol extraction method for lipid adapted from Folch et al. 23 
Histology and Morphometry of Carotid Arteries
The cuffed region of the right carotid artery was dissected from each animal and cut into 12 ring segments. Every second ring was fixed in 10% neutral BFS, sectioned at 6 /xm, and stained with hematoxylin and eosin for light microscopy and morphometry (6 rings per vessel). The left carotid artery was severed and removed at identical sites, then sampled and sectioned in the same way. Morphometric analyses were performed with a digitizing tablet interfaced to an IBM-AT- 
Fluorescence Immunocytochemistry
Four ring segments per vessel were snap-frozen in liquid nitrogen-cooled isopentane and OCT medium (Tissue-Tek, Miles Inc) and stored at -70°C for immunocytochemistry. Serial 10-/*m sections were cut and adhered to gelatin/chrome alum-coated slides. Sections were fixed in absolute acetone at -20°C (5 minutes) and allowed to air-dry (15 minutes). The tissue was preincubated in Tris-buffered saline (TBS) (0.05 mol/L Tris HC1, 0.145 mol/L NaCl, pH 7.4 to 7.6) and 10% normal sheep serum (20 minutes) to block any nonspecific binding of antibodies. Random sections were incubated overnight at 4°C with primary antibodies to macrophage (monoclonal mouse anti-rabbit macrophage, RAM-11; DAKO Corp) or a-smooth muscle actin (monoclonal mouse anti-human a-smooth muscle actin, HHF35; DAKO Corp). Primary antibodies were diluted (anti-macrophage, 1:50 and anti-actin, 1:100) in TBS and 1% normal sheep serum. After washing in three changes of TBS (3x 5 minutes), the sections were incubated for 1 hour with sheep anti-mouse immunoglobuiin (Silenus Laboratories) conjugated with fluorescein isothiocyanate isomer 1 (FITC). The antiserum was washed off with TBS ( 3 x 5 minutes), and the sections were mounted with coverslips and Vectashield mounting medium (Vector) for examination under the fluorescence microscope. The number of labeled macrophages in 6 random sections from each of 4 rings per vessel, 8 vessels per group (ie, 192 sections per group) was counted and averaged per section for each experimental group.
Statistics
For all analyses, paired t tests and Mann-Whitney U tests were performed on an IBM-compatible DX PC using SIGMA STAT software (Jandel Scientific). P<.05 was considered significant.
Results
Biological and Hematologic Parameters hLIF slowed the normal increase in body weight of the rabbits and indeed induced an initial decrease regardless of diet (Table) , such that after 2 weeks, the mean weights of non-hLIF-and hLIF-treated rabbits were significantly different (group 1, 2.47±0.12 kg versus group 2, 1.93+0.25 kg, normal diet; group 3, 2.54±0.10 kg versus group 4, 1.99±0.16 kg, cholesterol diet) (P=.01). Group 2 and 4 rabbits proceeded to gain weight during the following 2 weeks of treatment to be within the control weight ranges. LIF had no significant effect on spleen weight (group 1, 1.30±0.20 g versus group 2,1.51 ±0.35 g, normal diet; group 3, 1.50 ±0.55 g versus group 4, 1.53±0.50 g, cholesterol diet) or thymus weight (group 1, 3.40±0.49 g versus group 2, 3.21 ±0.55 g, normal diet; group 3, 3.70±0.55 g versus group 4, 3.30±0.60 g, cholesterol diet). Animal temperament and overall behavior remained constant throughout the experimental period. hLIF treatment resulted in a twofold to threefold increase in blood platelet number in both normolipidemic and hyperlipidemic rabbits (groups 2 and 4) compared with controls (groups 1 and 3) (Table) . This dramatic increase was observed within the first 7 days of treatment and was sustained until week 2 or 3 of treatment, after which platelet numbers decreased to be in the range of the non-hLIF-treated groups. There was no significant difference between groups 1 and 3 or between groups 2 and 4.
ESR was also increased significantly (P=.01) in both groups 2 and 4 up until week 3 of treatment compared with non-hLIF-treated rabbits (Table) . Again, there was no significant difference in ESR between groups 1 and 3 or groups 2 and 4.
In both groups 2 and 4, hLIF treatment resulted in a significant decrease in serum albumin concentrations (P<.001) by week 2 of treatment compared with control-treated animals (eg, group 1, 37.1 ±4.0 g/L versus group 4, 28.0±3.0 g/L). There was no significant difference between groups in serum calcium levels with or without hLIF treatment (eg, group 1,3.50±0.15 mmol/L versus group 4, 3.25 ±0.25 mmol/L).
hLIF and Plasma Cholesterol
As expected, cholesterol-fed rabbits displayed a significant (sixfold) increase in plasma cholesterol concentration compared with those fed normal rabbit chow, from approximately 600 to 3600 /xmol cholesterol/L plasma (P<.001) (Fig 1, left) . There was no change in plasma cholesterol levels of normolipidemic rabbits treated with hLIF compared with those of control normolipidemic animals. hLIF treatment of the cholesterol-fed rabbits, however, resulted in significantly lower plasma cholesterol levels (P=.O2), reducing concentrations by almost 20% (Fig 1, left) . Fig 1 (right) shows the cholesterol content of the individual plasma lipoproteins as affected by the experimental conditions. Lipoprotein cholesterol did not vary greatly in normolipidemic rabbits, regardless of treatment. Very-low-density lipoprotein (VLDL) tended to be prominent in normolipidemic plasma, although not to significant levels. Most striking, however, was the dramatic increase in low-density lipoprotein (LDL) and /3-VLDL associated with the elevated plasma cholesterol in hyperlipidemic rabbits. In reducing plasma cholesterol, hLIF decreased the LDL-associated cholesterol more significantly (P=.01) compared with the other lipoprotein species.
hLIF and Aortic Tissue Cholesterol (Aortic Arch)
Cholesterol levels were low in the aortic tissue of control normolipidemic rabbits, and normolipidemic rabbits treated with hLIF displayed no significant variation from these values (Fig 2) . Hyperlipidemia resulted in significant accumulation of cholesterol in the aortic (Fig 2) .
hLIF and Fatty Streak Formation
At death, normolipidemic rabbits administered saline had no lipid-filled lesions (fatty streaks) in the thoracic aorta, nor did hLIF-treated normolipidemic animals. Hyperlipidemia, however, induced significant thoracic aorta fatty streak formation (/ J <.001), which after hLIF treatment was significantly reduced, from 63.25±17.66% to 10.00±8.96% (P=.01) (Fig 3) .
hLIF and Neointimal Formation
At completion of the 28-day experimental period, a significant (Z'<.001) concentric neointima consisting of five to six cell layers was present in the region of the carotid artery underlying the Silastic cuff in nonhLIF-treated normolipidemic (Fig 4A) and hyperlipidemic (Fig 4C) rabbits. No significant difference between normal and cholesterol diet was observed in the extent of neointimal thickening, and in both cases, neointima composed 18.60±2.5% of the total vessel wall area (Fig 5) .
hLIF-treated normolipidemic and hyperlipidemic rabbits (Fig 4B and 4D , respectively) exhibited a 90% decrease (significant, F<.001) in neointimal formation that, when present, consisted of focal thickenings of one to two cell layers (Fig 4B) composing only 2.00±3.00% total vessel wall area (Fig 5) . 
hLIF and Monocyte Invasion of Vessel Wall
Staining with an a-smooth muscle actin antibody confirmed the SMC-rich nature of the neointimal thickening in both the control normal diet and cholesterolfed rabbits (groups 1 and 3) (Fig 6A) and illustrated the inhibitory effect of hLIF on neointimal formation ( Fig  6B) . No macrophages were present in neointimal tissue from normolipidemic rabbits, either control or hLIFtreated, as evidenced by staining with the anti-macrophage antibody RAM-11. Macrophages were, however, present in equal (large) numbers in the neointimal tissue of control and hLIF-treated hyperlipidemic rabbits (Fig 6C and 6D, respectively) 
Discussion
One of the first and most striking responses to the 30-)ug • kg" 1 • d" 1 dose of hLIF in the rabbit model, under both normal and hypercholesterolemic conditions, was a dramatic increase in platelet numbers (approximately 2.6-fold), equal to or greater than those observed after the injection of mice with the same amount of LIF on a per-body weight basis, 20 or the effect seen in mice of mqlti-colony stimulating factor, 24 thrombo'poietin, 25 and interleukin-6. 26 Short-term weight loss and an acute-phase response characterized by an accelerated ESR and a fall in serum albumin concentration were also observed, again consistent with previous observations on LIF-treated mice and primates. 20 -27 The crux of the present study, however, was to investigate the antiatherogenic effects of LIF. hLIF lowered the level of cholesterol both in the plasma and in aortic tissue in the hyperlipidemic rabbit. The decreased level of plasma cholesterol was mainly the result of a decrease in plasma LDL-associated cholesterol, although /3-VLDL was also decreased slightly. LDLs are derived from VLDLs after enzymatic interaction with lipoprotein lipase (LPL) on the capillary endothelium of various tissues. 28 LIF, an LPL inhibitor, 8 would theoretically prevent the hydrolysis of VLDL, reducing the quantity of circulating LDL and associated cholesterol and keeping that of VLDL elevated. However, the fact that both LDL-and )3-VLDL-associated cholesterol levels were decreased suggests that the LDL is being cleared by an additional or alternative mechanism and not solely by an LPL-inhibitory effect of hLIF. It is known that macrophage colony stimulating factor produces a dramatic decrease in plasma cholesterol 29 and that oncostatin M (a macrophage-derived regulatory factor) induces increased LDL and/or /3-VLDL uptake and increased LDL receptor expression (the B/E receptor) by liver cells in culture. 30 Oncostatin M is a glycoprotein cytokine that is structurally and functionally related to LIF 31 and is capable of binding the high-affinity LIF receptor, 32 possibly expressed by hepatocytes. 5 Plasma cholesterol may therefore be reduced via two separate actions of LIF, one of which leads to a decrease in LDL cholesterol through LPL inhibition and the other to a decrease in /3-VLDL and LDL cholesterol by increased /3-VLDL and LDL metabolism via the commonly recognized B/E receptor.
The observed decrease in level of aortic tissue cholesterol (and fatty streak formation) in the LIF-treated hyperlipidemic rabbits is undoubtedly related to the decrease in plasma cholesterol; that is, the less lipid in circulation, the lower the potential for subendothelial lipid accumulation in the vessel wall, resulting in the lack of fatty streak formation. However, the reduction in tissue cholesterol (=60%) was greater than that in plasma cholesterol (=20%), suggesting that additional mechanisms may be operating at the level of the vessel wall. It can also be argued that the plasma cholesterol data presented here were obtained at week 4, the completion of the experimental period, at which time the lowering effects may already be attenuated. Plasma cholesterol levels may have been even lower before week 4, thus accounting for the dramatic decrease in aortic tissue cholesterol and fatty streak formation.
At this point, it should be noted that after 4 weeks of hyperlipidic diet, plasma cholesterol levels in the non-hLIF-treated rabbits (group 3) reached approximately 3.80 mmol/L (147 mg/dL). This value is considerably lower than in previous studies involving 1% cholesterol feeding of rabbits, in which peak levels of cholesterol range between 10 and 12 mmol/L; basal levels in such studies are usually around the 1.25 mmol/L mark. 33 It is important to note that in this study, the average basal levels of circulating cholesterol in the normolipidemic, non-hLIF-treated rabbits (group 1) were 0.40 mmol/L. Thus, the fold increase in plasma cholesterol is consistent.
The most significant observation in this study is that hLIF almost completely prevented the development of a neointimal thickening in rabbits fed either a normolipidic or hyperlipidic diet after placement of a nonocclusive cuff around the right carotid artery. An extensive investigation by Kockx et al 19 revealed that the time course of development after the placement of a nonocclusive cuff on the rabbit carotid artery displays three phases: an early infiltration of the vessel wall by polymorphonuclear leukocytes (phase 1); SMC replication in the media (phase 2); and then gradual subendothelial SMC accumulation (phase 3) with deposition of collagen fibers and fibronectin within this neointima. The inhibitory effect of hLIF may be exerted at one or indeed each of these phases. However, the mechanism by which the Silastic cuff induces neointimal formation is unknown. In an experiment that involved the application of a thread presoaked in lipopolysaccharide (endotoxin) along a rat femoral artery, it was observed that neointimal formation resulted after monocyte invasion of the vessel wall. 34 The authors assumed a causal relationship between the two processes, with dexamethasone inhibiting both monocyte infiltration and SMC migration and proliferation within the intima. However, this does not appear to be the case with the LIF-induced inhibition of neointima formation, since the antibody RAM-11 revealed equal numbers of macrophages in the neointima of hyperlipidemic control rabbits and the subendothelial space of LIF-treated animals on a highcholesterol diet. Macrophages, however, were absent from the neointima of normolipidemic control rabbits and the subendothelial space of LIF-treated normolipidemic rabbits. This indicates that hyperlipidemia, in both the presence and absence of LIF, may lead to the retainment of leukocytes in the intima. It also indicates that the presence of monocytes/macrophages in the subendothelial space does not necessarily lead to myointimal thickening. LIF, however, may interfere with the function of the macrophage, affecting its production and/or secretion of cytokines/growth factors influencing smooth muscle growth. Indeed, a recent study by Villiger et al 11 showed that LIF induced the expression of interleukin-6 by human blood monocytes. If, as speculated above, the presence of monocytes/ macrophages in the subendothelial space does not necessarily lead to myointimal thickening, a direct action on SMCs by hLIF may not be excluded. hLIF may interfere with the SMC mitogenic process and thus its proliferative response to endogenous and/or exogenous mitogens. Indeed, it was the ability of LIF to suppress the clonogenicity of myeloid leukemic cells 1 -2 that led to the eventual purification and characterization of the molecule. A direct effect of hLIF on SMC phenotype is also a possibility. An inhibitory action that would prevent contractile-state SMCs from modulating to a synthetic state under pathological conditions would again interfere with the proliferative response and indeed SMC migration into the intima. Finally, hLIF may exert an action on SMCs that prevents their migration alone, independent of proliferation.
In conclusion, hLIF exerts an antiatherogenic effect in the thoracic aorta in hyperlipidemic states and inhibits the formation of neointima in the cuffed right carotid artery in both normolipidemia and hyperlipidemia. The antiatherogenic action of hLIF in the rabbit model appears to be twofold: (1) lowering of plasma cholesterol, thereby reducing the potential for tissue insudation of lipid resulting in fatty lesion development, and (2) inhibition of neointimal formation (SMC proliferation/migration) independent of diet and monocyte invasion of the vessel wall.
